Switch theme
Sign up to access all valuation multiples
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Company's products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
2016
155
Last FY Revenue n/a
LTM EBITDA -$72.3M
-$15.0M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nautilus Biotechnology has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$72.3M.
In the most recent fiscal year, Nautilus Biotechnology achieved revenue of n/a and an EBITDA of -$75.1M.
Nautilus Biotechnology expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nautilus Biotechnology valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$72.3M | XXX | -$75.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$80.6M | XXX | -$81.5M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$71.4M | XXX | -$70.8M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nautilus Biotechnology's stock price is $1.
Nautilus Biotechnology has current market cap of $94.5M, and EV of -$15.0M.
See Nautilus Biotechnology trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$15.0M | $94.5M | XXX | XXX | XXX | XXX | $-0.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nautilus Biotechnology has market cap of $94.5M and EV of -$15.0M.
Nautilus Biotechnology's trades at n/a EV/Revenue multiple, and 0.2x EV/EBITDA.
Equity research analysts estimate Nautilus Biotechnology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nautilus Biotechnology has a P/E ratio of -1.3x.
See valuation multiples for Nautilus Biotechnology and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $94.5M | XXX | $94.5M | XXX | XXX | XXX |
| EV (current) | -$15.0M | XXX | -$15.0M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.3x | XXX | -1.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNautilus Biotechnology's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.5M for the same period.
Nautilus Biotechnology's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nautilus Biotechnology's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nautilus Biotechnology and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 4% | XXX | 0% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Genomictree | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nautilus Biotechnology acquired XXX companies to date.
Last acquisition by Nautilus Biotechnology was XXXXXXXX, XXXXX XXXXX XXXXXX . Nautilus Biotechnology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nautilus Biotechnology founded? | Nautilus Biotechnology was founded in 2016. |
| Where is Nautilus Biotechnology headquartered? | Nautilus Biotechnology is headquartered in United States of America. |
| How many employees does Nautilus Biotechnology have? | As of today, Nautilus Biotechnology has 155 employees. |
| Who is the CEO of Nautilus Biotechnology? | Nautilus Biotechnology's CEO is Mr. Sujal M. Patel. |
| Is Nautilus Biotechnology publicy listed? | Yes, Nautilus Biotechnology is a public company listed on NAS. |
| What is the stock symbol of Nautilus Biotechnology? | Nautilus Biotechnology trades under NAUT ticker. |
| When did Nautilus Biotechnology go public? | Nautilus Biotechnology went public in 2021. |
| Who are competitors of Nautilus Biotechnology? | Similar companies to Nautilus Biotechnology include e.g. Zomedica, AnteoTech, Proteomics International, Biohit. |
| What is the current market cap of Nautilus Biotechnology? | Nautilus Biotechnology's current market cap is $94.5M |
| Is Nautilus Biotechnology profitable? | Yes, Nautilus Biotechnology is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Nautilus Biotechnology? | Nautilus Biotechnology's last 12 months EBITDA is -$72.3M. |
| What is the current EV/EBITDA multiple of Nautilus Biotechnology? | Current EBITDA multiple of Nautilus Biotechnology is 0.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
